On June 28, Daniel C. Montano, CEO of CardioVascular BioTherapeutics, Inc. (PINK:CVBT), proudly announced the company’s goal to fully meet SEC reporting requirements by the end of Q3 at the latest. Now, in the middle of Q4, CVBT is still a STOP-sign bearer on the pink sheets. Yet, CVBT stock has been doing incredibly well in the past few weeks.
As seen on the accompanying chart, CVBT has been showing definite signs of appreciation in value for more than a week now. Yesterday, in particular, CVBT gained 11% to close the session at a six-month high of $0.48 per share. What is more, even though a total of 727 thousand shares changed hands, which is CVBT’s third highest result since late-May, the company’s stock did not suffer any value loss.
Neither official corporate news, nor paid promotions in support of CVBT stock have come up for quite a while now. That is why, either investors are overly enthusiastic about the company’s soon-to-be-published audited financial reports for the past three years, or there are traders who might have some fairly positive inside information that has yet to surface.
No matter what happens during the upcoming session, the company’s CEO had better honour his commitment to upgrade the company’s market status to ensure a long-term chart run. Otherwise, what goes up now will most definitely come down in due course.
